zanidatamab
jazz pharma,zymeworks
[]
jiving with jazz after $325m opt-in, links her2 #bispecific to 84% survival after 18 months - more like this | #ascogi #adenocarcinoma #mgea #esophca #esophagealcancer #her2 #clincaldata #biotech 
Business intelligence for biotechs. We help #biotech innovators, investors, and business partners connect.